GALMED PHARMACEUTICALS LTD.: capital expenditure payments
Capital expenditure payments for GALMED PHARMACEUTICALS LTD. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All GALMED PHARMACEUTICALS LTD. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-01-01 to 2022-12-31. The SEC response was captured on 2026-09-20.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2022-01-01 | 2022-12-31 | 4,000 | USD | 2025-04-02 | 20-F · 0001641172-25-002362 |
| 2021-01-01 | 2021-12-31 | 11,000 | USD | 2024-04-04 | 20-F · 0001493152-24-013203 |
| 2020-01-01 | 2020-12-31 | 44,000 | USD | 2023-03-29 | 20-F · 0001493152-23-009478 |
| 2019-01-01 | 2019-12-31 | 12,000 | USD | 2022-05-02 | 20-F · 0001493152-22-011729 |
| 2018-01-01 | 2018-12-31 | 90,000 | USD | 2021-03-18 | 20-F · 0001104659-21-038205 |
| 2017-01-01 | 2017-12-31 | 12,000 | USD | 2020-03-12 | 20-F · 0001104659-20-032166 |
| 2016-01-01 | 2016-12-31 | 17,000 | USD | 2019-03-13 | 20-F · 0001144204-19-013601 |
| 2015-01-01 | 2015-12-31 | 159,000 | USD | 2018-03-13 | 20-F · 0001144204-18-014234 |
| 2014-01-01 | 2014-12-31 | 770,000 | USD | 2017-03-23 | 20-F · 0001144204-17-016148 |
| 2013-01-01 | 2013-12-31 | 13,000 | USD | 2016-03-22 | 20-F · 0001144204-16-089349 |
| 2012-01-01 | 2012-12-31 | 32,000 | USD | 2015-03-31 | 20-F · 0001144204-15-019665 |
Related financial histories
- GALMED PHARMACEUTICALS LTD.: total assets
- GALMED PHARMACEUTICALS LTD.: stockholders equity
- GALMED PHARMACEUTICALS LTD.: cash and cash equivalents
- GALMED PHARMACEUTICALS LTD.: net income or loss
- GALMED PHARMACEUTICALS LTD.: operating cash flow
- GALMED PHARMACEUTICALS LTD.: revenue
- GALMED PHARMACEUTICALS LTD.: financing cash flow
- GALMED PHARMACEUTICALS LTD.: investing cash flow
- GALMED PHARMACEUTICALS LTD.: retained earnings or deficit
- GALMED PHARMACEUTICALS LTD.: basic weighted-average shares
- GALMED PHARMACEUTICALS LTD.: diluted weighted-average shares
- GALMED PHARMACEUTICALS LTD.: basic earnings per share
- GALMED PHARMACEUTICALS LTD.: diluted earnings per share
- GALMED PHARMACEUTICALS LTD.: income tax expense or benefit
- GALMED PHARMACEUTICALS LTD.: net property, plant and equipment
- GALMED PHARMACEUTICALS LTD.: share-based compensation expense
- GALMED PHARMACEUTICALS LTD.: operating income or loss
- GALMED PHARMACEUTICALS LTD.: current assets
- GALMED PHARMACEUTICALS LTD.: current liabilities
- GALMED PHARMACEUTICALS LTD.: current accounts payable
- GALMED PHARMACEUTICALS LTD.: operating expenses
- GALMED PHARMACEUTICALS LTD.: research and development expense
Inspect the source
- Entity
- GALMED PHARMACEUTICALS LTD. / CIK 0001595353
- Captured
- 2026-09-20T09:24:38.274Z
- SEC response SHA-256
e6c06419a40da36331b99b1132d673f720f3b3c37535452f9147eca8f9a9ad80
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001595353.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))